We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
-10.1%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.63%
AUM
$1.98B
AUM Growth
+$65.7M
Cap. Flow
+$343M
Cap. Flow %
17.32%
Top 10 Hldgs %
50.43%
Holding
310
New
10
Increased
122
Reduced
100
Closed
37
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ESGU icon
251
iShares ESG Aware MSCI USA ETF
ESGU
$17.9B
$224K 0.01%
+2,670
New +$244K
IWS icon
252
iShares Russell Mid-Cap Value ETF
IWS
$15.6B
$224K 0.01%
2,201
+261
+13% +$29.2K
EZU icon
253
iShare MSCI Eurozone ETF
EZU
$9.64B
$214K 0.01%
5,891
+144
+3% +$5.77K
EXC icon
254
Exelon
EXC
$46.9B
$212K 0.01%
4,667
OXY icon
255
Occidental Petroleum
OXY
$56.8B
$211K 0.01%
3,587
-3
-0.1% -$184
KMI icon
256
Kinder Morgan
KMI
$71.7B
$210K 0.01%
+12,503
New +$234K
IVW icon
257
iShares S&P 500 Growth ETF
IVW
$73.8B
$204K 0.01%
3,388
-18
-0.5% -$1.19K
ENPH icon
258
Enphase Energy
ENPH
$4.96B
$200K 0.01%
1,025
KNOP icon
259
KNOT Offshore Partners
KNOP
$372M
$164K 0.01%
10,000
MRNS
260
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$164K 0.01%
33,879
+1,114
+3% +$6.78K
INVA icon
261
Innoviva
INVA
$1.55B
$161K 0.01%
10,926
-1,999
-15% -$32.7K
HBAN icon
262
Huntington Bancshares
HBAN
$34.4B
$145K 0.01%
+12,030
New +$160K
ISPC icon
263
iSpecimen
ISPC
$2.72M
$135K 0.01%
78
+35
+81% +$85.7K
VLY icon
264
Valley National Bancorp
VLY
$7.9B
$130K 0.01%
+12,500
New +$149K
AVEO
265
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$127K 0.01%
19,380
ADMA icon
266
ADMA Biologics
ADMA
$1.96B
$106K 0.01%
53,314
NAK
267
Northern Dynasty Minerals
NAK
$784M
$83K ﹤0.01%
318,950
MRSN
268
DELISTED
Mersana Therapeutics
MRSN
$69K ﹤0.01%
597
+22
+4% +$2.07K
HRTX icon
269
Heron Therapeutics
HRTX
$93.9M
$43K ﹤0.01%
15,536
+448
+3% +$1.8K
ITRM
270
DELISTED
Iterum Therapeutics
ITRM
$36K ﹤0.01%
11,960
+208
+2% +$778
RBBN icon
271
Ribbon Communications
RBBN
$377M
$30K ﹤0.01%
10,030
FUBO icon
272
FuboTV Inc
FUBO
$261M
$25K ﹤0.01%
+833
New +$38.8K
OTLK icon
273
Outlook Therapeutics
OTLK
$183M
$10K ﹤0.01%
+500
New +$14.4K
A icon
274
Agilent Technologies
A
$39.1B
-1,578
Closed -$209K
BIZD icon
275
VanEck BDC Income ETF
BIZD
$1.59B
-18,366
Closed -$329K

Similar funds

Grimes & Company's Q2 2022 Portfolio in Review

As of Q2 2022, Grimes & Company held 310 positions worth $1.98B, up 3.4% from $1.92B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Grimes & Company deployed $343M of net new capital in Q2 2022, opening 10 new positions and adding to 122 existing holdings. Its largest new stake was iShares 0-1 Year Treasury Bond ETF: 2,728,540 shares worth $300M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 17% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was State Street Technology Select Sector SPDR ETF, an estimated $56.5M trimmed.

  • Grimes & Company's largest Q2 2022 buy was iShares 0-1 Year Treasury Bond ETF: 2,728,540 shares worth $300M.
  • Grimes & Company added most to JPMorgan Ultra-Short Income ETF in Q2 2022, an estimated $316M increase.
  • Grimes & Company's biggest Q2 2022 reduction was State Street Technology Select Sector SPDR ETF, cutting an estimated $56.5M.
  • Grimes & Company fully exited State Street Industrial Select Sector SPDR ETF in Q2 2022, selling an estimated $25.4M.
  • Grimes & Company's ten largest holdings make up 50% of its $1.98B portfolio in Q2 2022.
  • Grimes & Company opened 10 new positions and closed 37 in Q2 2022.
  • Grimes & Company's portfolio value rose 3.4% quarter-over-quarter to $1.98B.

Based on Grimes & Company's 13F filing for Q2 2022, filed 22 Jul 2022.